Arrowhead Pharma To Present Three-Year Data From PALISADE Study And Open-Label Extension At American Heart Association Scientific Sessions 2026
Benzinga Newsdesk 4 hours ago
News
– Detailed Results from the Phase 1/2a Study of ARO-DIMER-PA, the First Dual-Functional Investigational RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia, Will Be Presented at Late-breaking Featured Science
– Detailed Results from the Phase 1/2a Study of ARO-DIMER-PA, the First Dual-Functional Investigational RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia, Will Be Presented at Late-breaking Featured Science Session.05 on Saturday, November 7 –
– Pooled SHASTA-3/4 Analysis of Triglyceride Lowering and Acute Pancreatitis (AP) Risk Reduction with Plozasiran in Severe Hypertriglyceridemia (sHTG) Also To Be Presented at Late-Breaking Featured Science Session.05 –
–Long Term Efficacy and Safety of Plozasiran in Patients with Familial Chylomicronemia Syndrome: Three-Year Data from the PALISADE Study and the Open-Label Extension Will Be Presented in Moderated Poster Session –
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced today that it will present important data at this week’s American Heart Association Scientific Sessions in Chicago.